YouSigma- the web's most extensive resource for information
Allergan, Inc. (SWOT Analysis) - July 2011

Go to Home Page

Download PDF Version!

“SWOT is an acronym for the internal Strengths and Weaknesses of a firm and the environmental Opportunities and Threats facing that firm. SWOT analysis is a widely used technique through which managers create a quick overview of a company’s strategic situation. The technique is based on the assumption that an effective strategy derives from a sound “fit” between a firm’s internal resources (strengths and weaknesses) and its external situation (opportunities and threats). A good fit maximizes a firm’s strengths and opportunities and minimizes its weaknesses and threats. Accurately applied, this simple assumption has powerful implications for the design of a successful strategy.”

Allergan, Inc. Company Overview 

Allergan is a multi-specialty health care company. It is engaged in the discovery, development and commercialization of innovative pharmaceuticals, biologics and medical devices. Allergan’s products address ophthalmic, neurological, medical aesthetics, medical dermatological, breast aesthetics, obesity intervention and other specialty markets. The company is headquartered in Irvine, California and employed approximately 9,200 people as of December 31, 2010.

Strengths, Weaknesses, Opportunities and Threats (SWOT)

Location of Factor






  • Enhanced focus on niche markets providing Allergan with strategic advantages
  • Relatively well insulated portfolio from generic erosion driving top-line growth
  • Growing non-prescription pharmaceutical businesses complementing Botox sales


  • High dependence on Botox sales exposing Allergan’s business to concentration risk
  • Series of late-stage pipeline setbacks limiting drug candidates’ commercial potential



  • Expanded indication to drive Botox uptake
  • Further expansion into complementary markets could help reduce dependency on single therapeutic market
  • Favorable demographics and social trends could drive Botox sales


  • Loss of further market share to competing neurotoxin products
  • Earlier than anticipated arrival of generic Restasis and Combigan
About YouSigma

Find charities worthy of your support and donate

Copyright and Disclaimer
"Allergan, Inc. (SWOT Analysis)";